

HB0500S01 compared with HB0500

~~{Omitted text}~~ shows text that was in HB0500 but was omitted in HB0500S01

inserted text shows text that was not in HB0500 but was inserted into HB0500S01

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

Controlled Substance Modifications

2025 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Jennifer Dailey-Provost

Senate Sponsor: Kirk A. Cullimore

LONG TITLE

General Description:

This bill amends provisions related to the Controlled Substances Act.

Highlighted Provisions:

This bill:

- classifies amanita muscaria as a controlled substance~~{-}~~ ; and
- provides for the automatic rescheduling of a certain type of psilocybin if rescheduled by the federal government.

Money Appropriated in this Bill:

None

Other Special Clauses:

None

AMENDS:

58-37-4 , as last amended by Laws of Utah 2024, Chapter 298 , as last amended by Laws of Utah 2024, Chapter 298

HB0500

HB0500 compared with HB0500S01

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **58-37-4** is amended to read:

58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

(C) Acetylmethadol;

(D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);

(E) Allylprodine;

(F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(G) Alphameprodine;

(H) Alphamethadol;

(I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

(J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- piperidinyl]-N-phenylpropanamide);

(K) Benzylpiperazine;

(L) Benzethidine;

(M) Betacetylmethadol;

(N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-phenylpropanamide);

(O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;

HB0500 compared with HB0500S01

51	(P) Betameprodine;
52	(Q) Betamethadol;
53	(R) Betaprodine;
54	(S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
55	(T) Clonitazene;
56	(U) Cyclopropyl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
58	(V) Dextromoramide;
59	(W) Diampromide;
60	(X) Diethylthiambutene;
61	(Y) Difenoxin;
62	(Z) Dimenoxadol;
63	(AA) Dimepheptanol;
64	(BB) Dimethylthiambutene;
65	(CC) Dioxaphetyl butyrate;
66	(DD) Dipipanone;
67	(EE) Ethylmethylthiambutene;
68	(FF) Etizolam (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
70	(GG) Etonitazene;
71	(HH) Etoxeridine;
72	(II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] furan-2-carboxamide);
74	(JJ) Furethidine;
75	(KK) Hydroxypethidine;
76	(LL) Ketobemidone;
77	(MM) Levomoramide;
78	(NN) Levophenacylmorphane;
79	(OO) Methoxyacetyl fentanyl (2-Methoxy-N-(1-phenylethylpiperidin-4-yl)-N-acetamide);
81	(PP) Morpheridine;
82	(QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
83	(RR) Noracymethadol;
84	(SS) Norlevorphanol;
85	(TT) Normethadone;

HB0500 compared with HB0500S01

- 86 (UU) Norpipanone;
87 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidiny] propanamide);
89 (WW) Para-fluoroisobutyryl fentanyl (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide);
91 (XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
92 (YY) Phenadoxone;
93 (ZZ) Phenampromide;
94 (AAA) Phenomorphan;
95 (BBB) Phenoperidine;
96 (CCC) Piritramide;
97 (DDD) Proheptazine;
98 (EEE) Properidine;
99 (FFF) Propiram;
100 (GGG) Racemoramide;
101 (HHH) Tetrahydrofuran fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
carboxamide);
103 (III) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidiny]- propanamide;
104 (JJJ) Tilidine;
105 (KKK) Trimeperidine;
106 (LLL) 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2-
phenylethyl)-4-piperidy]- N-phenylpropanamide);
108 (MMM) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidiny]-N-phenylpropanamide);
110 (NNN) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known as U-47700;
and
112 (OOO) 4-cyano CUMYL-BUTINACA.
113 (ii) Unless specifically excepted or unless listed in another schedule, any of the following opium
derivatives, their salts, isomers, and salts of isomers when the existence of the salts, isomers, and
salts of isomers is possible within the specific chemical designation:
117 (A) Acetorphine;
118 (B) Acetyldihydrocodeine;
119 (C) Benzylmorphine;

HB0500 compared with HB0500S01

- 120 (D) Codeine methylbromide;
- 121 (E) Codeine-N-Oxide;
- 122 (F) Cyprenorphine;
- 123 (G) Desomorphine;
- 124 (H) Dihydromorphine;
- 125 (I) Drotebanol;
- 126 (J) Etorphine (except hydrochloride salt);
- 127 (K) Heroin;
- 128 (L) Hydromorphenol;
- 129 (M) Methyldesorphine;
- 130 (N) Methylhydromorphine;
- 131 (O) Morphine methylbromide;
- 132 (P) Morphine methylsulfonate;
- 133 (Q) Morphine-N-Oxide;
- 134 (R) Myrophine;
- 135 (S) Nicocodeine;
- 136 (T) Nicomorphine;
- 137 (U) Normorphine;
- 138 (V) Pholcodine; and
- 139 (W) Thebacon.
- 140 (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as used in this Subsection (2) (a)(iii) only, "isomer" includes the optical, position, and geometric isomers:
 - 146 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
 - 148 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
 - 150 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;

HB0500 compared with HB0500S01

- 153 (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- α -methylphenethylamine;
2,5-DMA;
- 155 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
- 156 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- α -methylphenethylamine;
paramethoxyamphetamine, PMA;
- 158 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
- 159 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5-dimethoxy- α -
methylphenethylamine; "DOM"; and "STP";
- 161 (I) 3,4-methylenedioxy amphetamine;
- 162 (J) 3,4-methylenedioxymethamphetamine (MDMA);
- 163 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- α -
methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
- 166 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy- α -
methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
- 169 (M) 3,4,5-trimethoxy amphetamine;
- 170 (N) Bufotenine, some trade and other names: 3-(β -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
mappine;
- 173 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
- 174 (P) Dimethyltryptamine, some trade or other names: DMT;
- 175 (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga;
- 178 (R) Lysergic acid diethylamide;
- 179 (S) Marijuana;
- 180 (T) Mescaline;
- 181 (U) Parahexyl, some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
dibenzo[b,d]pyran; Synhexyl;
- 184 (V) Peyote, meaning all parts of the plant presently classified botanically as *Lophophora williamsii*
Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and
every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or
extracts (Interprets 21 USC 812(c), Schedule I(c) (12));

HB0500 compared with HB0500S01

- 189 (W) N-ethyl-3-piperidyl benzilate;
190 (X) N-methyl-3-piperidyl benzilate;
191 (Y) Psilocybin, except as provided in Subsection (3);
192 (Z) Psilocyn;
193 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis (cannabis plant),
except for marijuana as defined in Subsection 58-37-2(1)(aa)(i)(E), as well as synthetic equivalents
of the substances contained in the cannabis plant, or in the resinous extractives of Cannabis, sp.
and/or synthetic substances, derivatives, and their isomers with similar chemical structure and
pharmacological activity to those substances contained in the plant, such as the following: Δ 1 cis
or trans tetrahydrocannabinol, and their optical isomers Δ 6 cis or trans tetrahydrocannabinol, and
their optical isomers Δ 3,4 cis or trans tetrahydrocannabinol, and its optical isomers, and since
nomenclature of these substances is not internationally standardized, compounds of these structures,
regardless of numerical designation of atomic positions covered;
204 (BB) Ethylamine analog of phencyclidine, some trade or other names: N-ethyl-1-
phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1-phenylcyclohexyl)ethylamine,
cyclohexamine, PCE;
207 (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 1-(1-phenylcyclohexyl)-
pyrrolidine, PCPy, PHP;
209 (DD) Thiophene analog of phencyclidine, some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-
piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
212 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
213 (iv) Unless specifically excepted or unless listed in another schedule, any material compound, mixture,
or preparation which contains any quantity of the following substances having a depressant effect on
the central nervous system, including its salts, isomers, and salts of isomers when the existence of
the salts, isomers, and salts of isomers is possible within the specific chemical designation:
218 (A) Mecloqualone; and
219 (B) Methaqualone.
220 (v) Any material, compound, mixture, or preparation containing any quantity of the following
substances having a stimulant effect on the central nervous system, including their salts, isomers,
and salts of isomers:

223

HB0500 compared with HB0500S01

- (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazamine;
- 225 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
- 227 (C) Fenethylamine;
- 228 (D) Methcathinone, some other names: 2-(methylamino)-propionophenone; alpha-(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of optical isomers;
- 233 (E) (\pm)cis-4-methylaminorex ((\pm)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazamine);
- 234 (F) N-ethylamphetamine; and
- 235 (G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 237 (vi) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including their optical isomers, salts, and salts of isomers, subject to temporary emergency scheduling:
- 240 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
- 241 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thienylfentanyl).
- 242 (vii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate (gamma hydroxybutyric acid), including its salts, isomers, and salts of isomers.
- 246 (b) Schedule II:
- 247 (i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 251 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextropropion, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:
- 254 (I) Raw opium;

HB0500 compared with HB0500S01

- 255 (II) Opium extracts;
256 (III) Opium fluid;
257 (IV) Powdered opium;
258 (V) Granulated opium;
259 (VI) Tincture of opium;
260 (VII) Codeine;
261 (VIII) Ethylmorphine;
262 (IX) Etorphine hydrochloride;
263 (X) Hydrocodone;
264 (XI) Hydromorphone;
265 (XII) Metopon;
266 (XIII) Morphine;
267 (XIV) Oxycodone;
268 (XV) Oxymorphone; and
269 (XVI) Thebaine;
270 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or identical with any
of the substances referred to in Subsection (2)(b)(i)(A), except that these substances may not include
the isoquinoline alkaloids of opium;
274 (C) Opium poppy and poppy straw;
275 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt,
compound, derivative, or preparation which is chemically equivalent or identical with any of
these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of
isomers and derivatives, whether derived from the coca plant or synthetically produced, except the
substances may not include decocainized coca leaves or extraction of coca leaves, which extractions
do not contain cocaine or ecgonine; and
282 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either liquid, solid, or
powder form which contains the phenanthrene alkaloids of the opium poppy.
285 (ii) Unless specifically excepted or unless listed in another schedule, any of the following opiates,
including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the
existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation,
except dextrophan and levopropoxyphene:

HB0500 compared with HB0500S01

- 290 (A) Alfentanil;
291 (B) Alphaprodine;
292 (C) Anileridine;
293 (D) Bezitramide;
294 (E) Bulk dextropropoxyphene (nondosage forms);
295 (F) Carfentanil;
296 (G) Dihydrocodeine;
297 (H) Diphenoxylate;
298 (I) Fentanyl;
299 (J) Isomethadone;
300 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol, levomethadyl acetate, or
LAAM;
302 (L) Levomethorphan;
303 (M) Levorphanol;
304 (N) Metazocine;
305 (O) Methadone;
306 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
307 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
309 (R) Pethidine (meperidine);
310 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
311 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
312 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
313 (V) Phenazocine;
314 (W) Piminodine;
315 (X) Racemethorphan;
316 (Y) Racemorphan;
317 (Z) Remifentanil; and
318 (AA) Sufentanil.
319 (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances having a stimulant effect on
the central nervous system:

HB0500 compared with HB0500S01

- 322 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
323 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
324 (C) Phenmetrazine and its salts; and
325 (D) Methylphenidate.
- 326 (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances having a depressant effect on
the central nervous system, including its salts, isomers, and salts of isomers when the existence of
the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 331 (A) Amobarbital;
332 (B) Glutethimide;
333 (C) Pentobarbital;
334 (D) Phencyclidine;
335 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and 1-
piperidinocyclohexanecarbonitrile (PCC); and
337 (F) Secobarbital.
- 338 (v)
- (A) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of Phenylacetone.
- 341 (B) Some of these substances may be known by trade or other names: phenyl-2-propanone; P2P; benzyl
methyl ketone; and methyl benzyl ketone.
- 343 (vi) Nabilone, another name for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-
hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 346 (vii) A drug product or preparation that contains any component of marijuana, including
tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and
scheduled by the Drug Enforcement Administration in Schedule II of the federal Controlled
Substances Act, Title II, P.L. 91-513.
- 350 (c) Schedule III:
- 351 (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances having a stimulant effect on
the central nervous system, including its salts, isomers whether optical, position, or geometric, and

HB0500 compared with HB0500S01

salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 357 (A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant
substances listed in Schedule II, which compounds, mixtures, or preparations were listed on
August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal
Regulations, and any other drug of the quantitative composition shown in that list for those drugs or
which is the same except that it contains a lesser quantity of controlled substances;
- 363 (B) Benzphetamine;
- 364 (C) Chlorphentermine;
- 365 (D) Clortermine; and
- 366 (E) Phendimetrazine.
- 367 (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances having a depressant effect on
the central nervous system:
- 370 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any
salt of any of them, and one or more other active medicinal ingredients which are not listed in any
schedule;
- 373 (B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt
of any of these drugs which is approved by the United States Food and Drug Administration for
marketing only as a suppository;
- 376 (C) Any substance which contains any quantity of a derivative of barbituric acid or any salt of any of
them;
- 378 (D) Chlorhexadol;
- 379 (E) Buprenorphine;
- 380 (F) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts
of isomers, for which an application is approved under the federal Food, Drug, and Cosmetic Act,
Section 505;
- 383 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: \pm -2-(2-
chlorophenyl)-2-(methylamino)-cyclohexanone;
- 385 (H) Lysergic acid;
- 386 (I) Lysergic acid amide;

HB0500 compared with HB0500S01

- 387 (J) Methypylon;
388 (K) Sulfondiethylmethane;
389 (L) Sulfonethylmethane;
390 (M) Sulfonmethane; and
391 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a tiletamine-
zolazepam combination product: Telazol, some trade or other names for tiletamine: 2-
(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam: 4-(2-
fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrzapon.
397 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food
and Drug Administration approved drug product, some other names for dronabinol: (6aR-
trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-
(trans)-tetrahydrocannabinol.
402 (iv) Nalorphine.
403 (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation containing limited quantities of any of the following narcotic drugs, or their salts
calculated as the free anhydrous base or alkaloid:
407 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage
unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
410 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage
unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
413 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15
milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
416 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15
milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized
therapeutic amounts;
419 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per
dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
422 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams
per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic
amounts;
425

HB0500 compared with HB0500S01

- (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and
- 428 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
- 431 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:
- 434 (A) Boldenone;
- 435 (B) Chlorotestosterone (4-chlortestosterone);
- 436 (C) Clostebol;
- 437 (D) Dehydrochlormethyltestosterone;
- 438 (E) Dihydrotestosterone (4-dihydrotestosterone);
- 439 (F) Drostanolone;
- 440 (G) Ethylestrenol;
- 441 (H) Fluoxymesterone;
- 442 (I) Formebolone (formebolone);
- 443 (J) Mesterolone;
- 444 (K) Methandienone;
- 445 (L) Methandranone;
- 446 (M) Methandriol;
- 447 (N) Methandrostenolone;
- 448 (O) Methenolone;
- 449 (P) Methyltestosterone;
- 450 (Q) Mibolerone;
- 451 (R) Nandrolone;
- 452 (S) Norethandrolone;
- 453 (T) Oxandrolone;
- 454 (U) Oxymesterone;
- 455 (V) Oxymetholone;
- 456 (W) Stanolone;
- 457 (X) Stanozolol;

HB0500 compared with HB0500S01

- 458 (Y) Testolactone;
459 (Z) Testosterone; and
460 (AA) Trenbolone.
- 461 (vii) Anabolic steroids expressly intended for administration through implants to cattle or other
nonhuman species, and approved by the Secretary of Health and Human Services for use, may not
be classified as a controlled substance.
- 464 (viii) A drug product or preparation that contains any component of marijuana, including
tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and
scheduled by the Drug Enforcement Administration in Schedule III of the federal Controlled
Substances Act, Title II, P.L. 91-513.
- 468 (ix) Nabiximols.
- 469 (x) Amanita Muscaria.
- 470 (d) Schedule IV:
- 471 (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation containing not more than 1 milligram of difenoxin and not less than 25 micrograms of
atropine sulfate per dosage unit, or any salts of any of them.
- 475 (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances, including its salts, isomers,
and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within
the specific chemical designation:
- 480 (A) Alprazolam;
481 (B) Barbitol;
482 (C) Bromazepam;
483 (D) Butorphanol;
484 (E) Camazepam;
485 (F) Carisoprodol;
486 (G) Chloral betaine;
487 (H) Chloral hydrate;
488 (I) Chlordiazepoxide;
489 (J) Clobazam;
490 (K) Clonazepam;

HB0500 compared with HB0500S01

491 (L) Clorazepate;
492 (M) Clotiazepam;
493 (N) Cloxazolam;
494 (O) Delorazepam;
495 (P) Diazepam;
496 (Q) Dichloralphenazone;
497 (R) Estazolam;
498 (S) Ethchlorvynol;
499 (T) Ethinamate;
500 (U) Ethyl loflazepate;
501 (V) Fludiazepam;
502 (W) Flunitrazepam;
503 (X) Flurazepam;
504 (Y) Halazepam;
505 (Z) Haloxazolam;
506 (AA) Ketazolam;
507 (BB) Loprazolam;
508 (CC) Lorazepam;
509 (DD) Lormetazepam;
510 (EE) Mebutamate;
511 (FF) Medazepam;
512 (GG) Meprobamate;
513 (HH) Methohexital;
514 (II) Methylphenobarbital (mephobarbital);
515 (JJ) Midazolam;
516 (KK) Nimetazepam;
517 (LL) Nitrazepam;
518 (MM) Nordiazepam;
519 (NN) Oxazepam;
520 (OO) Oxazolam;
521 (PP) Paraldehyde;

HB0500 compared with HB0500S01

- 522 (QQ) Pentazocine;
523 (RR) Petrichloral;
524 (SS) Phenobarbital;
525 (TT) Pinazepam;
526 (UU) Prazepam;
527 (VV) Quazepam;
528 (WW) Temazepam;
529 (XX) Tetrazepam;
530 (YY) Tramadol;
531 (ZZ) Triazolam;
532 (AAA) Zaleplon; and
533 (BBB) Zolpidem.
534 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains any quantity of the following substances, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible.
538 (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
544 (A) Cathine ((+)-norpseudoephedrine);
545 (B) Diethylpropion;
546 (C) Fencamfamine;
547 (D) Fenproporex;
548 (E) Mazindol;
549 (F) Mefenorex;
550 (G) Modafinil;
551 (H) Pemoline, including organometallic complexes and chelates thereof;
552 (I) Phentermine;
553 (J) Pipradrol;
554 (K) Sibutramine; and

HB0500 compared with HB0500S01

- 555 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 556 (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
- 560 (vi) A drug product or preparation that contains any component of marijuana and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule IV of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 564 (e) Schedule V:
- 565 (i) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
- 570 (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
- 571 (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
- 573 (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
- 575 (D) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
- 577 (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
- 578 (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; and
- 580 (G) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.
- 584 (ii) A drug product or preparation that contains any component of marijuana, including cannabidiol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 588 (iii) Gabapentin.
- 591 (3) If the federal government schedules the pharmaceutical composition of crystallinepolymorph psilocybin in a schedule that is not schedule I, that composition is deemed scheduled under this

HB0500 compared with HB0500S01

section in the same schedule that the composition is scheduled under 21 U.S.C. Sec. 812 and 21 C.F.R. Sec. 1308.14.

595

Section 2. **Effective date.**

Effective Date.

This bill takes effect on May 7, 2025.

3-5-25 12:19 PM